The mRNA Vaccines and Therapeutics Market is estimated at $3.43 billion in 2018. The Standardized Therapeutic Cancer mRNA Vaccines segment held a share of 35.47% in 2018 and is projected to grow with a CAGR of 9.77% in next ten years.
How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 184-page report you will receive 130 charts– all unavailable elsewhere.
The 184-page report provides clear detailed insight into the mRNA Vaccines and Therapeutics Market. Discover the key drivers and challenges affecting the market.
Report Scope
• Revenue and growth forecasts from 2019 to 2029 for the mRNA Vaccines and Therapeutics market
• Revenue and growth forecasts from 2019 to 2029 for the mRNA Vaccines and Therapeutics market by type:
• Standardized Therapeutic Cancer mRNA Vaccines
• Individualized Therapeutic Cancer mRNA Vaccines
• Therapeutic Infectious Disease mRNA Vaccines
• mRNA Therapeutic for Other Diseases
• Revenue and growth forecasts from 2019 to 2029 for the mRNA Vaccines and Therapeutics market by Mechanism of Action:
• Bioengineered Vaccine
• Gene Therapy (Gene Silencing/Suppression)
• Gene Transcription (Protein Generation)
• Cell Therapy
• Monoclonal Antibody
• Others
• Revenue and growth forecasts from 2019 to 2029 for the leading regional and national markets:
• North America: the revenues are further broken down into the US and Canada
• Europe: the revenues are further broken down into the UK, Germany, France, Italy and Spain
• Asia-Pacific: the revenues are further broken down into China, Japan and India
• Rest of the World: the revenues are further broken down into Brazil, Mexico, Russia and South Africa
• Discussion and profiles of the leading players in the mRNA Vaccines and Therapeutics market:
• Argos Therapeutics, Inc.
• BioNTech AG
• CureVac AG
• eTheRNA Immunotherapies
• ethris GmbH
• In-Cell-Art
• Moderna Therapeutics
• Sangamo Therapeutics, Inc.
• Tiba Biotech
• Translate Bio, Inc.
• Discussion on mRNA & Delivery Technologies covering Arcelis Technology, Flow Electroporation Technology, Hybrid mRNA Technology, Lipid Nanoparticle (LNP) mRNA Technology, Nanotaxi Technology, RNArt & RNAntibody Technology, UNA & LUNAR Technologies, RNActive Technology, Self-Amplifying mRNA (SAM) Technology, TriMix Technology
• Qualitative analysis of factors that drive and restrain the mRNA Vaccines and Therapeutics market. Trends analysis of the mRNA Vaccines and Therapeutics market.
• mRNA Vaccines and Therapeutics R&D pipeline analysis
• Key Questions Answered by this Report:
• How is the mRNA vaccines and therapeutics market evolving?
• What is driving and restraining the mRNA vaccines and therapeutics market?
• What are the market shares of the leading segments of the mRNA vaccines and therapeutics market in 2018?
• What will be the main driver of the overall market from 2019 to 2029?
• How will the market shares of the leading national markets change by 2029 and which country will lead the market in 2029?
• How will the industry evolve during the period between 2019 and 2029?
• Who are the leading companies in this market?
Visiongain’s study is intended for anyone requiring commercial analyses for the mRNA Vaccines and Therapeutics market. You find data, trends and predictions.
Buy our report today mRNA Vaccines and Therapeutics Market : Standardized Therapeutic Cancer mRNA Vaccines, Individualized Therapeutic Cancer mRNA Vaccines, Therapeutic Infectious Disease mRNA Vaccines, mRNA Therapeutic for Other Diseases, Bioengineered Vaccine, Gene Transcription, Monoclonal Antibody, Gene Therapy, Cell Therapy.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
1. Report Overview
1.1 Global mRNA Vaccines and Therapeutics Market Overview
1.2 Global mRNA Vaccines and Therapeutics Market Segmentation
1.3 Overview of Findings
1.4 Structure of the Report
1.5 Why You Should Read This Report
1.6 How This Report Delivers
1.7 Main Questions Answered by this Report
1.8 Who is this Report for?
1.9 Research and Analysis Methods
1.10 Frequently Asked Questions (FAQ)
1.11 Associated Reports
1.12 About Visiongain
2. Introduction to mRNA Vaccines and Therapeutics
2.1 History of mRNA Vaccines & Therapeutics Development
2.2 Incidence and Prevalence of Chronic Diseases and Major Infectious Diseases
2.3 Prevention and Treatment Using mRNA Vaccines & Therapeutics
2.3.1 mRNA Modifications
2.3.2 mRNA Efficiencies
2.3.3 Adjuvant/Stimulant & Carrier Technologies for mRNA-based Vaccines
2.3.4 Carriers for mRNA-based Protein & Antibody Therapeutics
3. Introduction of mRNA & Delivery Technologies
3.1 Ex vivo mRNA Loading
3.1.1 Arcelis Technology
3.1.2 Flow Electroporation Technology
3.2 In vivo Carrier & mRNA
3.2.1 Hybrid mRNA Technology
3.2.2 Lipid Nanoparticle (LNP) mRNA Technology
3.2.3 Nanotaxi Technology
3.2.4 RNArt & RNAntibody Technology
3.2.5 UNA & LUNAR Technologies
3.3 mRNA Vaccines & Stimulants / Adjuvants
3.3.1 RNActive Technology
3.3.2 Self-Amplifying mRNA (SAM) Technology
3.3.3 TriMix Technology
4. Global mRNA Vaccines & Therapeutics: Market Size and Forecast 2019-2029
4.1 mRNA Vaccines and Therapeutics Market Overview, 2018
4.2 The World mRNA Vaccines and Therapeutics Market
4.3 World mRNA Vaccines and Therapeutics Market: Sales Forecast 2019-2029
4.4 Changing Market Shares by Region 2018-2029
5. mRNA Vaccines and Therapeutics Market: Drivers, Restraints, and Trends Analysis 2019-2029
5.1 mRNA Vaccines and Therapeutics Market: Drivers 2019-2029
5.1.1 Rising Adoption of Personalized Medicine for Effective Treatment
5.1.2 Advantages Offered by mRNA-based Products
5.1.3 Rising Funding by Pharmaceutical Companies and Government Organizations
5.2 mRNA Vaccines and Therapeutics Market: Restraints 2019-2029
5.2.1 Delivery of mRNA therapeutics and vaccines
5.2.2 Stringent Government Regulations for mRNA-based Product Approvals
5.3 mRNA Vaccines and Therapeutics Market: Trends 2019-2029
5.3.1 Rising adoption of gene therapy-based products
6. mRNA Vaccines & Therapeutics by Type: Market Size and Forecast 2019-2029
6.1 Market Forecast 2019-2029
6.2 Market Share of mRNA Vaccines and Therapeutics by Type
6.2.1 Standardized Therapeutic Cancer mRNA Vaccines: Market Forecast, 2019-2029
6.2.2 Individualized Therapeutic Cancer mRNA Vaccines: Market Forecast, 2019-2029
6.2.3 Therapeutic Infectious Disease mRNA Vaccines: Market Forecast, 2019-2029
6.2.4 mRNA Therapeutic for Other Diseases: Market Forecast, 2019-2029
7. mRNA Vaccines & Therapeutics by Mechanism of Action: Market Size and Forecast 2019-2029
7.1 Market Forecast 2019-2029
7.2 Market Share of mRNA Vaccines and Therapeutics by Mechanism of Action
7.2.1 Bioengineered Vaccine: Market Forecast, 2019-2029
7.2.2 Gene Therapy (Gene Silencing/Suppression): Market Forecast, 2019-2029
7.2.3 Gene Transcription (Protein Generation): Market Forecast, 2019-2029
7.2.4 Cell Therapy: Market Forecast, 2019-2029
7.2.5 Monoclonal Antibody: Market Forecast, 2019-2029
7.2.6 Others: Market Forecast, 2019-2029
8. mRNA Vaccines & Therapeutics Regional Market: Market Size and Forecast 2019-2029
8.1 Leading National Markets of mRNA Vaccines & Therapeutics 2019-2029
8.2 North America mRNA Vaccines & Therapeutics: Market Size and Forecast 2019-2029
8.2.1 The US mRNA Vaccines and Therapeutics: Market Forecast 2019-2029
8.2.2 Canada mRNA Vaccines and Therapeutics: Market Forecast 2019-2029
8.3 Europe mRNA Vaccines & Therapeutics: Market Size and Forecast 2018-2029
8.3.1 Germany mRNA Vaccines and Therapeutics: Market Forecast 2019-2029
8.3.2 UK mRNA Vaccines and Therapeutics Market: Forecast 2019-2029
8.3.3 French mRNA Vaccines and Therapeutics Market: Forecast 2019-2029
8.3.4 Italian mRNA Vaccines and Therapeutics: Market Forecast 2019-2029
8.3.5 Spanish mRNA Vaccines and Therapeutics: Market Forecast 2019-2029
8.4 Asia-Pacific mRNA Vaccines & Therapeutics Market Size and Forecast 2019-2029
8.4.1 Japanese mRNA Vaccines and Therapeutics: Market Forecast 2019-2029
8.4.2 Chinese mRNA Vaccines and Therapeutics: Market Forecast 2019-2029
8.4.3 Indian mRNA Vaccines and Therapeutics: Market Forecast 2019-2029
8.5 Row mRNA Vaccines & Therapeutics Market Size and Forecast 2018-2029
8.5.1 Brazilian mRNA Vaccines and Therapeutics: Market Forecast 2019-2029
8.5.2 Mexico mRNA Vaccines and Therapeutics: Market Forecast 2019-2029
8.5.3 Russia mRNA Vaccines and Therapeutics: Market Forecast 2019-2029
8.5.4 South Africa mRNA Vaccines and Therapeutics: Market Forecast 2019-2029
9. mRNA Vaccines & Therapeutics R&D Pipeline Analysis, 2018
9.1 Promising Pipeline Molecules Analysis
9.2 Standardized mRNA Cancer Vaccines
9.3 Therapeutic mRNA Infectious Disease Vaccines
9.4 Individualized mRNA Cancer Vaccines
9.5 Replicon RNA Infectious Disease Vaccines
9.6 Prophylactic mRNA Infectious Disease Vaccines
9.7 mRNA Protein Therapeutics for Ornithine TransCarbomylase Deficiency
9.8 mRNA Protein Therapeutics for Cancer and Cardiovascular Diseases
9.9 mRNA Protein Therapeutics for Cystic Fibrosis
9.10 mRNA Protein Therapeutics for Other Genetic Diseases
9.11 Therapeutic mRNA-based Gene Editing
9.12 mRNA Antibody Therapeutics
10. Leading Companies in the mRNA Vaccines and Therapeutics Market
10.1 Moderna Therapeutics
10.1.1 Product Portfolio
10.1.2 Financial Overview
10.1.3 Strategic Developments
10.2 Sangamo Therapeutics
10.2.1 Product Portfolio
10.2.2 Financial Overview
10.2.3 Strategic Developments
10.3 Argos Therapeutics
10.3.1 Product Portfolio
10.3.2 Financial Overview
10.3.3 Strategic Developments
10.4 CureVac
10.4.1 Product Portfolio
10.4.2 Financial Overview
10.4.3 Strategic Developments
10.5 Translate Bio
10.5.1 Product Portfolio
10.5.2 Financial Overview
10.5.3 Strategic Developments
10.6 BioNTech
10.6.1 Product Portfolio
10.6.2 Financial Overview
10.6.3 Strategic Developments
10.7 In-Cell-Art
10.7.1 Product Portfolio
10.7.2 Financial Overview
10.7.3 Strategic Developments
10.8 eTheRNA Immunotherapies
10.8.1 Product Portfolio
10.8.2 Financial Overview
10.8.3 Strategic Developments
10.9 ethris GmbH
10.9.1 Product Portfolio
10.9.2 Financial Overview
10.9.3 Strategic Developments
10.10 Tiba Biotech
10.10.1 Product Portfolio
10.10.2 Financial Overview
10.10.3 Strategic Developments
11. Conclusion
11.1 The World mRNA Vaccines and Therapeutics Market in 2018-2029
11.2 Current Leading mRNA Vaccines and Therapeutics Segments
11.3 Leading mRNA Vaccines and Therapeutics Companies
11.4 Leading Regional Markets
Appendices
Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain report evaluation form
List of Tables
Table 4.1 Global mRNA Vaccines and Therapeutics Market Forecast Revenue ($bn), AGR (%), CAGR (%), 2019-2029
Table 6.1 Global mRNA Vaccines and Therapeutics Market Forecast by Type: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
Table 6.2 Global Standardized Therapeutic Cancer mRNA Vaccines Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029
Table 6.3 Global Individualized Therapeutic Cancer mRNA Vaccines Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029
Table 6.4 Global Therapeutic Infectious Disease mRNA Vaccines Market Forecast: Revenue ($bn), AGR (%), CAGR (%) 2019-2029
Table 6.5 Global mRNA Therapeutic for Other Diseases Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029
Table 7.1 Global mRNA Vaccines and Therapeutics Market Forecast by Mechanism of Action: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
Table 7.2 Global Bioengineered Vaccine Market Forecast: Revenue ($bn), AGR (%), CAGR (%) 2019-2029
Table 7.3 Global Gene Therapy (Gene Silencing/Suppression) Market Forecast: Revenue ($bn), AGR (%), CAGR (%) 2019-2029
Table 7.4 Global Gene Transcription (Protein Generation) Market Forecast: Revenue ($bn), AGR (%), CAGR (%) 2019-2029
Table 7.5 Global Cell Therapy Market Forecast: Revenue ($bn), AGR (%), CAGR (%) 2019-2029
Table 7.6 Global Monoclonal Antibody Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029
Table 7.7 Global Other Mechanism of Actions Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029
Table 8.1 World mRNA Vaccines and Therapeutics Market by Region: Revenue ($bn) and Market Share (%) 2018 and 2029
Table 8.2 Global mRNA Vaccines and Therapeutics Market Forecast by Region: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
Table 8.3 North America mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
Table 8.4 North America mRNA Vaccines and Therapeutics Market Forecast by Country: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
Table 8.5 US mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2029
Table 8.6 Canada mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
Table 8.7 Europe mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
Table 8.8 Europe mRNA Vaccines and Therapeutics Market Forecast by Country: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
Table 8.9 Germany mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
Table 8.10 UK mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
Table 8.11 French mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
Table 8.12 Italian mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
Table 8.13 Spanish mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2029
Table 8.14 Asia-Pacific mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
Table 8.15 Asia-Pacific mRNA Vaccines and Therapeutics Market Forecast by Country: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
Table 8.16 Japanese mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
Table 8.17 Chinese mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
Table 8.18 Indian mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2029
Table 8.19 RoW mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
Table 8.20 RoW mRNA Vaccines and Therapeutics Market Forecast by Country: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
Table 8.21 Brazilian mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
Table 8.22 Mexico mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
Table 8.23 Russia mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
Table 8.24 South Africa mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
Table 9.1 Promising mRNA Vaccines and Therapies Pipeline Molecules Analysis, 2018
Table 9.2 Standardized mRNA Cancer Vaccines Pipeline Molecules Analysis, 2018
Table 9.3 Standardized mRNA Cancer Vaccines Pipeline Molecules Analysis, 2018
Table 9.4 Individualized mRNA Cancer Vaccines Pipeline Molecules Analysis, 2018
Table 9.5 Prophylactic mRNA Infectious Disease Vaccines Pipeline Molecules Analysis, 2018
Table 9.6 mRNA Protein Therapeutics for Ornithine TransCarbomylase Deficiency Pipeline Molecules Analysis, 2018
Table 9.7 mRNA Protein Therapeutics for Cancer and Cardiovascular Diseases Pipeline Molecules Analysis, 2018
Table 9.8 mRNA Protein Therapeutics for Cystic Fibrosis Pipeline Molecules Analysis, 2018
Table 9.9 mRNA Protein Therapeutics for Cystic Fibrosis Pipeline Molecules Analysis, 2018
Table 9.10 mRNA Protein Therapeutics for Cystic Fibrosis Pipeline Molecules Analysis, 2018
Table 9.11 mRNA Antibody Therapeutics Pipeline Molecules Analysis, 2018
Table 10.1 Overview: Moderna Therapeutics
Table 10.2 Moderna Therapeutics: Product Portfolio
Table 10.3 Recent Developments: Moderna Therapeutics
Table 10.4 Overview: Sangamo Therapeutics
Table 10.5 Sangamo Therapeutics: Product Portfolio
Table 10.6 Recent Developments: Sangamo Therapeutics, Inc.
Table 10.7 Overview: Argos Therapeutics
Table 10.8 Argos Therapeutics: Product Portfolio
Table 10.9 Recent Developments: Argos Therapeutics, Inc.
Table 10.10 Overview: CureVac
Table 10.11 CureVac: Product Portfolio
Table 10.12 Recent Developments: CureVac AG
Table 10.13 Overview: Translate Bio
Table 10.14 Translate Bio: Product Portfolio
Table 10.15 Recent Developments: Translate Bio
Table 10.16 Overview: BioNTech
Table 10.17 BioNTech: Product Portfolio
Table 10.18 Recent Developments: BioNTech
Table 10.19 Overview: In-Cell-Art
Table 10.20 In-Cell-Art: Product Portfolio
Table 10.21 Recent Developments: Translate Bio
Table 10.22 Overview: eTheRNA Immunotherapies
Table 10.23 eTheRNA Immunotherapies: Product Portfolio
Table 10.24 Recent Developments: Translate Bio
Table 10.25 Overview: Ethris GmbH
Table 10.26 Ethris GmbH: Product Portfolio
Table 10.27 Recent Developments: ethris GmbH
Table 10.28 Overview: Tiba Biotech
Table 10.29 Tiba Biotech: Product Portfolio
List of Figures
Figure 4.1 Global mRNA Vaccines and Therapeutics Market Forecast Revenue ($bn), AGR (%) 2019-2029
Figure 4.2 Global mRNA Vaccines and Therapeutics Market Forecast Share (%) by Region 2019-2029
Figure 5.1 mRNA Vaccines and Therapeutics Market: Drivers and Restraints 2019-2029
Figure 6.1 Global mRNA Vaccines and Therapeutics Market Forecast by Type: Revenue ($bn), 2019-2029
Figure 6.2 Global mRNA Vaccines and Therapeutics Market Forecast by Type: Market Share (%), 2019-2029
Figure 6.3 Global mRNA Vaccines and Therapeutics Market Forecast by Type: Market Shares (%), 2018
Figure 6.4 Global mRNA Vaccines and Therapeutics Market Forecast by Type: Market Shares (%), 2024
Figure 6.5 Global mRNA Vaccines and Therapeutics Market Forecast by Type: Market Shares (%), 2029
Figure 6.6 Global Standardized Therapeutic Cancer mRNA Vaccines Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 6.7 Global Individualized Therapeutic Cancer mRNA Vaccines Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 6.8 Global Therapeutic Infectious Disease mRNA Vaccines Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 6.9 Global mRNA Therapeutic for Other Diseases Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 7.1 Global mRNA Vaccines and Therapeutics Market Forecast by Mechanism of Action: Revenue ($bn) 2019-2029
Figure 7.2 Global mRNA Vaccines and Therapeutics Market Forecast by Mechanism of Action: Market Share (%) 2019-2029
Figure 7.3 Global mRNA Vaccines and Therapeutics Market Forecast by Mechanism of Action: Market Shares (%), 2018
Figure 7.4 Global mRNA Vaccines and Therapeutics Market Forecast by Mechanism of Action: Market Shares (%), 2024
Figure 7.5 Global mRNA Vaccines and Therapeutics Market Forecast by Mechanism of Action: Market Shares (%), 2029
Figure 7.6 Global Bioengineered Vaccine Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 7.7 Global Gene Therapy (Gene Silencing/Suppression) Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 7.8 Global Gene Transcription (Protein Generation) Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 7.9 Global Cell Therapy Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 7.10 Global Monoclonal Antibody Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 7.11 Global Other Mechanism of Actions Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 8.1 Global mRNA Vaccines and Therapeutics Market by Region: Revenues (%), 2018
Figure 8.2 Global mRNA Vaccines and Therapeutics Market by Region: Revenues (%), 2024
Figure 8.3 Global mRNA Vaccines and Therapeutics Market by Region: Revenues (%), 2029
Figure 8.4 North America mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 8.5 North America mRNA Vaccines and Therapeutics Market Forecast by Region: Share (%) 2019-2029
Figure 8.6 US mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 8.7 Canada mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 8.8 Europe mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 8.9 Europe mRNA Vaccines and Therapeutics Market by Country: Share (%), 2019-2029
Figure 8.10 Germany mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn) and AGR (%), 2018-2029
Figure 8.11 UK mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 8.12 French mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 8.13 Italian mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 8.14 Spanish mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn) and AGR (%), 2018-2029
Figure 8.15 Asia-Pacific mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 8.16 Asia-Pacific mRNA Vaccines and Therapeutics Market by Country: Share (%), 2019-2029
Figure 8.17 Japanese mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 8.18 Chinese mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 8.19 Indian mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn) and AGR (%), 2018-2029
Figure 8.20 RoW mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 8.21 RoW mRNA Vaccines and Therapeutics Market by Country: Share (%), 2018-2029
Figure 8.22 Brazilian mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 8.23 Mexico mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 8.24 Russia mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 8.25 South Africa mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 10.1 Moderna Therapeutics: Financial Overview, 2016-2018
Figure 10.2 Sangamo Therapeutics: Financial Overview, 2016-2018
Figure 10.3 Argos Therapeutics: Financial Overview, 2016-2018
Figure 11.1 Global mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn), AGR (%) 2019-2029
Figure 11.2 Global mRNA Vaccines and Therapeutics Market Forecast by Country: Share (%) 2019-2029
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
